1. P1057: REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE. (23rd June 2022) Authors: Harrison, C.; Mascarenhas, J.; Abraham, P.; Nadal, J. A.; Balanean, A.; McBride, A.; Kish, J. K.; Liassou, D.; Feinberg, B. A.; Gerds, A. T. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 947 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1060: REAL-WORLD CLINICAL OUTCOMES AFTER 3 AND 6 MONTHS OF TREATMENT WITH FEDRATINIB FOLLOWING RUXOLITINIB FAILURE. (23rd June 2022) Authors: Mascarenhas, J.; Gerds, A. T.; Kish, J. K.; Abraham, P.; Balanean, A.; Nadal, J. A.; Liassou, D.; Feinberg, B. A.; McBride, A.; Harrison, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 950 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗